View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Psychiatry News

SPONSORED CONTENT
Save
SPONSORED CONTENT
March 26, 2024
4 min read
Save

BLOG: Equity: Buyback rights, forfeiture and vesting

BLOG: Equity: Buyback rights, forfeiture and vesting

In our last post, we saw how rollover equity fits into the overall consideration paid to a selling physician owner of a physician practice.

SPONSORED CONTENT
March 25, 2024
1 min read
Save

Abnormal brain connectivity observed in youth with ADHD, although with small effect size

Abnormal brain connectivity observed in youth with ADHD, although with small effect size

Researchers identified differences in resting-state subcortico-cortical connectivity between youth with and without ADHD by analyzing almost 10,000 functional brain images, according to data published in The American Journal of Psychiatry.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
March 22, 2024
6 min read
Save

Q&A: Multifaceted approach key to address ‘many different drivers’ of physician burnout

Q&A: Multifaceted approach key to address ‘many different drivers’ of physician burnout

The COVID-19 pandemic has had a significant impact on the overall well-being of the health care workforce.

SPONSORED CONTENT
March 22, 2024
2 min read
Save

Treating patients with CVD for anxiety, depression helps lower heart-related outcomes

Treating patients with CVD for anxiety, depression helps lower heart-related outcomes

In patients with heart failure or coronary artery disease who also had anxiety and/or depression, treatment for their mental health condition was linked to better clinical outcomes, researchers reported.

SPONSORED CONTENT
March 21, 2024
1 min read
Save

Bristol Myers acquires Karuna, including novel muscarinic neuropsychiatric drug

Bristol Myers acquires Karuna, including novel muscarinic neuropsychiatric drug

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

SPONSORED CONTENT
March 21, 2024
1 min read
Save

Patients with depression showed improvement in spine-related disability after surgery

Patients with depression showed improvement in spine-related disability after surgery

Although patients with depression presented with and maintained worse spine disease severity after lumbar spine surgery vs. those without depression, researchers found these groups experienced a similar degree of postoperative improvement.

SPONSORED CONTENT
March 20, 2024
1 min read
Save

Children with AD, learning disabilities more likely to have learning, memory difficulties

Children with AD, learning disabilities more likely to have learning, memory difficulties

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

SPONSORED CONTENT
March 20, 2024
3 min read
Save

BLOG: The enormous potential of small actions

BLOG: The enormous potential of small actions

When I first entered the medical profession more than 30 years ago, I was taken by the amount of trash that was produced in the emergency department where I volunteered.

SPONSORED CONTENT
March 20, 2024
2 min read
Save

Link between psychedelic use, manic symptoms in teens may be associated with genetics

Link between psychedelic use, manic symptoms in teens may be associated with genetics

While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.

SPONSORED CONTENT
March 19, 2024
1 min read
Save

FDA grants breakthrough designation to psilocybin analog for major depressive disorder

FDA grants breakthrough designation to psilocybin analog for major depressive disorder

The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.

View more